Latest Breaking News On - Michael bishop institute - Page 1 : comparemela.com

Chengdu, China (PRUnderground) March 1st, 2021 Anticancer Biosciences is applying its synthetic lethality expertise for better cancer therapies. The identification of novel antimitotic agents that do not lead to severe side effects is much significant in the present day oncology drug development. At the J. Michael Bishop Institute of Cancer Research (MBICR), China’s world-leading cancer research Centre, there are many advanced research initiatives in this context. A recently published study from our Natural Product Drug Discovery Group (NPDD) highlights a novel screening method in uncovering the next generation of antimitotic natural compounds. The study, entitled ‘Purification, identification, and characterization of two benzophenanthridine alkaloids from Corydalis longicalcarata rhizomes with anti-mitotic and polyploidy-inducing activities’, was published in “Phytochemistry Letters”, an Official Journal of the Phytochemical Society of Europe, on 7th January 2021. The r

Jing zhangJ michael bishopJinhua liJ michael bishop institute of cancer researchJournal of the phytochemical society europeNatural product drug discovery groupAnticancer bioscience ltdAnticancer biosciencesBishop instituteCancer researchOfficial journalPhytochemical societyAnticancer bioscienceDun yangMichael bishop instituteNew antimitotic cancer therapeutics